IL6 and breast carcinoma: The above-mentioned findings, suggesting involvement of IL-6 in TME Stimulation-driven effects in HR+/HER2− breast cancer cells, have led us to determine whether STAT3, the canonical transcription factor that is activated by IL-6 [57,58], has regulatory roles in this system.